Oncotype DX not cost-effective for low-risk breast cancer
(HealthDay)—The multigene expression test Oncotype DX (ODX) is not cost-effective for women with breast cancer who are at low risk
Read more
(HealthDay)—The multigene expression test Oncotype DX (ODX) is not cost-effective for women with breast cancer who are at low risk
Read moreThe genetics and ageing rate of elephants could hold clues to helping us find better ways to fight cancer and
Read moreMiddle aged women in Australia aren’t getting the message about the proven link between alcohol consumption and breast cancer, at
Read moreInduced pluripotent stem cells, the workhorse of many regenerative medicine projects, start out as differentiated cells that are reprogrammed to
Read morePhysicians may soon have a new way to measure the efficacy or failure of hormone therapy for breast cancer patients,
Read moreA remarkable recent increase in the diagnosis of vocal-cord cancer in young adults appears to be the result of infection
Read moreMillennials with obesity suffer more often from cancer Overweight and obesity can favor the development of cancer. Doctors found that
Read moreMore and more institutions opt for E-cigarette Smoking can lower your risk for cancer diseases that are associated with the
Read moreThe National Cancer Institute (NCI) estimate that doctors diagnosed well over 1,700,00 new cases of cancer in 2018, and more
Read moreThe ten biggest threats to Health in the year 2019 The world is facing numerous health challenges. New waves of
Read more